Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679126 | 1.00 | CTSL (0.58) | CTSLCTSBCTSSF2ALDH1A1 | |
| SCHEMBL29678933 | 0.96 | CTSL (0.58) | CTSLCTSBCTSSF2ALDH1A1 | |
| SCHEMBL29679334 | 0.92 | CTSL (0.58) | CTSLCTSBCTSSF2CASP1 | |
| SCHEMBL24502886 | 0.83 | CTSS (0.53) | CTSLCTSBCTSSCTSKROCK2 | |
| SCHEMBL31584094 | 0.83 | CTSS (0.53) | CTSLCTSBCTSSCTSKROCK2 | |
| SCHEMBL29679086 | 0.81 | CTSL (0.56) | CTSLCTSBCTSSF2ALDH1A1 | |
| SCHEMBL22919853 | 0.81 | CTSL (0.56) | CTSLCTSBCTSSF2ALDH1A1 | |
| SCHEMBL7151822 | 0.80 | ALDH1A1 (0.74) | CTSLCTSBCTSSALDH1A1ALOX15 | |
| SCHEMBL329686 | 0.80 | ALDH1A1 (0.74) | CTSLCTSBCTSSALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL7928050 | 0.79 | ALDH1A1 (0.72) | CTSLCTSBCTSSALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | CTSL 1672/4885CTSB 1487/4885CTSS 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.